Search
Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalSipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. … The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.
Regorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalRegorafenib is an orally-administered inhibitor of multiple kinases.
Categories: UGT1A9 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexDinutuximab
go.drugbank.com/drugs/DB09077ApprovedInvestigationalDinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly … least a partial response to prior first-line multiagent, multimodality therapy.
Ferric cation
go.drugbank.com/drugs/DB13949ApprovedWithdrawnIron is a transition metal with a symbol Fe and atomic number 26. By mass, it is the most common element on Earth. … Iron deficiency may be characterized without the development of anemia, and may result in functional impairments affecting cognitive development and immunity mechanisms, as well as infant or maternal mortality
Vosoritide
go.drugbank.com/drugs/DB11928ApprovedInvestigationalEndogenous CNP, first described in 1998, is primarily responsible for the stimulation of chondrocytes and long bone growth via activity at the NPR-B receptor, making it an attractive target in the treatment … of a peptidase-resistant formulation has allowed for its use as a viable treatment option in achondroplasia.
Voxilaprevir
go.drugbank.com/drugs/DB12026ApprovedInvestigationalwith an HCV regimen containing sofosbuvir without an NS5A inhibitor [L935]. … Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV)
Fingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigational[A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. … Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.
Categories: Sphingosine 1-phosphate Receptor Modulator, Sphingosine 1 Phosphate Receptor ModulatorsIvosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigational[A248745] It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma … Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexHydroxyethyl cellulose
go.drugbank.com/drugs/DB11602ApprovedIt is often used as an ingredient in ophthalmic pharmaceutical preparations such as artificial tear solutions and adjunct agent in topical drug formulations to facilitate the delivery of drugs with hydrophobic … It is used as a key ingredient in many household cleaning products, lubricants and cosmetics due to its non-ionic and water-soluble nature.
Salts: Hydroxyethyl cellulose (100 MPa.s at 2%), Hydroxyethyl cellulose (140 MPa.s at 5%)Categories: Compounds used in a research, industrial, or household settingTetracosactide
go.drugbank.com/drugs/DB01284ApprovedInvestigationalTetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. … The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration.